Formulation Development and in Vitro Evaluation of Orally Disintegrating Tablets Containing Rizatriptan Benzoate

The present work aims to prepare and evaluate twelve different formulations of orally disintegrating tablets (ODT's) containing Rizatriptan benzoate using various superdisintegrants like SSG, Crospovidone and Croscarmellose sodium by direct compression method to enhance patient compliance. The tablets were evaluated for pre and post compression studies and found to be within the limits. Based on the disintegrating time and dissolution studies, formulation F11 prepared by using the super disintegrants SSG and Croscarmellose sodium in combination was found to be best formulation. The disintegration time was very less for optimized formulation F11 (18 sec), drug release was complete and very fast (within 18 minutes 99.9%) when compared with other prepared formulations. DSC and FTIR data revealed that no interactions takes place between the drug and polymers used in the optimized formulation. Stability studies were conducted for optimized formulation F11 and found to be stable which retained their original properties with minor differences. Oral disintegrating tablets are suitable dosage forms in disease conditions like migraine as these dosage forms are patient compliant as well as show rapid onset of action as they are quick dissolving dosage forms.